Publication:
Meropenem decreases serum level of valproic acid

dc.contributor.buuauthorNacarküçük, Ergün
dc.contributor.buuauthorSağlam, Halil
dc.contributor.buuauthorOkan, Mehmet Sait
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.contributor.orcid0000-0003-0710-5422
dc.contributor.researcheridC-7392-2019
dc.contributor.scopusid6602924559
dc.contributor.scopusid35612700100
dc.contributor.scopusid6701707256
dc.date.accessioned2021-08-31T07:49:26Z
dc.date.available2021-08-31T07:49:26Z
dc.date.issued2004-09
dc.description.abstractConcomitant administration of meropenem has been reported to decrease serum level of valproic acid both in humans and in animals. This report describes three children who required simultaneous administration of valproic acid and meropenem. Meropenem rapidly decreased serum valproic acid concentration to sub-therapeutic levels in all three children, and serum valproic acid levels were returned to therapeutic levels in a short time after discontinuing simultaneous meropenem therapy. Valproic acid was not changed to another antiepileptic agent, because no seizure activity was observed. To our knowledge, this is the first case report on the simultaneous administration of meropenem and valproic acid in childhood. In conclusion, it is clear that concomitant meropenem administration decreases serum valproic acid concentration, and we believe that there may be no need to change the antiepileptic drug during this period, provided that the patient has no seizure. More detailed studies are required.
dc.identifier.citationNacarküçük, E. vd. (2004). “Meropenem decreases serum level of valproic acid”. Pediatric Neurology, 31(3), 232-234.
dc.identifier.endpage234
dc.identifier.issn0887-8994
dc.identifier.issue3
dc.identifier.pubmed15351028
dc.identifier.scopus2-s2.0-4544265039
dc.identifier.startpage232
dc.identifier.urihttps://doi.org/10.1016/j.pediatrneurol.2004.03.014
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S088789940400219
dc.identifier.urihttp://hdl.handle.net/11452/21569
dc.identifier.volume31
dc.identifier.wos000224077600016
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier Science
dc.relation.journalPediatric Neurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNeurosciences & neurology
dc.subjectPediatrics
dc.subjectSafety profile
dc.subjectCarbapenem
dc.subjectPharmacokinetics
dc.subjectPanipenem
dc.subjectRabbits
dc.subjectPlasma
dc.subjectRats
dc.subject.emtreeCeftazidime
dc.subject.emtreeMeropenem
dc.subject.emtreeTobramycin
dc.subject.emtreeValproic acid
dc.subject.emtreeVancomycin
dc.subject.emtreeAdolescent
dc.subject.emtreeCase report
dc.subject.emtreeCerebral palsy
dc.subject.emtreeChild
dc.subject.emtreeClinical feature
dc.subject.emtreeDose calculation
dc.subject.emtreeDrug blood level
dc.subject.emtreeDrug brain level
dc.subject.emtreeDrug glucuronidation
dc.subject.emtreeDrug withdrawal
dc.subject.emtreeFemale
dc.subject.emtreeHospital admission
dc.subject.emtreeHuman
dc.subject.emtreeMale
dc.subject.emtreePatient monitoring
dc.subject.emtreePneumonia
dc.subject.emtreePriority journal
dc.subject.emtreeSeizure
dc.subject.emtreeSeizure susceptibility
dc.subject.meshAdolescent
dc.subject.meshDrug interactions
dc.subject.meshDrug therapy, combination
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshMale
dc.subject.meshThienamycins
dc.subject.meshValproic acid
dc.subject.scopusCarbapenems; Valproic Acid; Acylamino Acid Releasing Enzyme
dc.subject.wosClinical neurology
dc.subject.wosPediatrics
dc.titleMeropenem decreases serum level of valproic acid
dc.typeArticle
dc.wos.quartileQ2 (Pediatrics)
dc.wos.quartileQ3 (Clinical neurology)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: